메뉴 건너뛰기




Volumn 28, Issue 35, 2010, Pages 5182-5187

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North central cancer treatment group study N05C5

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; HYPSO; KERATOLYTIC AGENT; LACTIC ACID; PLACEBO; UNCLASSIFIED DRUG; UREA;

EID: 79951912347     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.1431     Document Type: Article
Times cited : (63)

References (29)
  • 1
    • 77952606821 scopus 로고    scopus 로고
    • Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies
    • Clark AS, Vahdat LT: Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Etiology and emerging therapies. Support Cancer Ther 1:213-218, 2004
    • (2004) Support Cancer Ther , vol.1 , pp. 213-218
    • Clark, A.S.1    Vahdat, L.T.2
  • 2
    • 0035476911 scopus 로고    scopus 로고
    • Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
    • DOI 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
    • Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001 (Pubitemid 32952493)
    • (2001) Cancer , vol.92 , Issue.7 , pp. 1759-1768
    • Blum, J.L.1    Dieras, V.2    Russo, P.M.L.3    Horton, J.4    Rutman, O.5    Buzdar, A.6    Osterwalder, B.7
  • 4
    • 0034778024 scopus 로고    scopus 로고
    • Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
    • DOI 10.1023/A:1012281104865
    • Oshaughnessy JA, Blum J, Moiseyenko V, et al: Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254, 2001 (Pubitemid 32994752)
    • (2001) Annals of Oncology , vol.12 , Issue.9 , pp. 1247-1254
    • O'Shaughnessy, J.A.1    Blum, J.2    Moiseyenko, V.3    Jones, S.E.4    Miles, D.5    Bell, D.6    Rosso, R.7    Mauriac, L.8    Osterwalder, B.9    Burger, H.-U.10    Laws, S.11
  • 8
    • 4244063621 scopus 로고    scopus 로고
    • Use of "Bag Balm" as topical treatment of palmer-plantar erythrodysesthsia syndrome (PPES) in patients receiving selected chemotherapeutic agents
    • suppl; abstr 1632
    • Chin SF, Tchen N, Oza AM, et al: Use of "Bag Balm" as topical treatment of palmer-plantar erythrodysesthsia syndrome (PPES) in patients receiving selected chemotherapeutic agents. Proc Am Soc Clin Oncol 20:409a, 2001 (suppl; abstr 1632)
    • (2001) Proc Am Soc Clin Oncol , vol.20
    • Chin, S.F.1    Tchen, N.2    Oza, A.M.3
  • 10
    • 0034231616 scopus 로고    scopus 로고
    • Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management
    • Nagore E, Insa A, Sanmartín O: Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome: Incidence, recognition and management. Am J Clin Dermatol 1:225-234, 2000
    • (2000) Am J Clin Dermatol , vol.1 , pp. 225-234
    • Nagore, E.1    Insa, A.2    Sanmartín, O.3
  • 11
    • 0002640816 scopus 로고    scopus 로고
    • Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: Updated results and analysis of dose modifications
    • abstr 693
    • Blum J, Jones S, Buzdar A, et al: Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated MBC: Updated results and analysis of dose modifications. Eur J Cancer 37, 2001 (abstr 693)
    • (2001) Eur J Cancer , vol.37
    • Blum, J.1    Jones, S.2    Buzdar, A.3
  • 13
    • 77958110977 scopus 로고    scopus 로고
    • Novel and effective management of capecitabine induced hand foot syndrome
    • Batra Cancer Center: suppl; abstr 8105
    • Pendharkar D, Goyal H, Batra Cancer Center: Novel and effective management of capecitabine induced hand foot syndrome. J Clin Oncol 22:751, 2004 (suppl; abstr 8105)
    • (2004) J Clin Oncol , vol.22 , pp. 751
    • Pendharkar, D.1    Goyal, H.2
  • 16
    • 0016119633 scopus 로고
    • Control of keratinization with alpha-hydroxy acids and related compounds: I. Topical treatment of ichthyotic disorders
    • Van Scott EJ, Yu RJ: Control of keratinization with alpha-hydroxy acids and related compounds: I. Topical treatment of ichthyotic disorders. Arch Dermatol 110:586-590, 1974
    • (1974) Arch Dermatol , vol.110 , pp. 586-590
    • Van Scott, E.J.1    Yu, R.J.2
  • 17
    • 0024511939 scopus 로고
    • Alpha hydroxy acids: Procedures for use in clinical practice
    • Van Scott EJ, Yu RJ: Alpha hydroxy acids: Procedures for use in clinical practice. Cutis 43:222-228, 1989 (Pubitemid 19088743)
    • (1989) Cutis , vol.43 , Issue.3 , pp. 222-228
    • Van, S.E.J.1    Yu, R.J.2
  • 19
    • 0033778443 scopus 로고    scopus 로고
    • Chemotherapy-induced acral erythema: Report of a case and immunohistochemical findings
    • Tsuruta D, Mochida K, Hamada T, et al: Chemotherapy-induced acral erythema: Report of a case and immunohistochemical findings. Clin Exp Dermatol 25:386-388, 2000
    • (2000) Clin Exp Dermatol , vol.25 , pp. 386-388
    • Tsuruta, D.1    Mochida, K.2    Hamada, T.3
  • 20
    • 0016799829 scopus 로고
    • Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
    • Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
    • (1975) Biometrics , vol.31 , pp. 103-115
    • Pocock, S.J.1    Simon, R.2
  • 21
    • 41949099104 scopus 로고    scopus 로고
    • Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study
    • suppl; abstr 9007
    • Lee S, Lee S, Chun Y, et al: Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: Results of a randomized double-blind placebo-controlled study. J Clin Oncol 25:494s, 2007 (suppl; abstr 9007)
    • (2007) J Clin Oncol , vol.25
    • Lee, S.1    Lee, S.2    Chun, Y.3
  • 23
    • 0036174497 scopus 로고    scopus 로고
    • Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience
    • DOI 10.1081/CNV-120000360
    • Abushullaih S, Saad ED, Munsell M, et al: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest 20:3-10, 2002 (Pubitemid 34151055)
    • (2002) Cancer Investigation , vol.20 , Issue.1 , pp. 3-10
    • Abushullaih, S.1    Saad, E.D.2    Munsell, M.3    Hoff, P.M.4
  • 24
    • 5644269852 scopus 로고    scopus 로고
    • Coming to grips with hand-foot syndrome: Insights from clinical trials evaluating capecitabine
    • (Williston Park) discussion 1173-1176, 1181-1184
    • Scheithauer W, Blum J: Coming to grips with hand-foot syndrome: Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 18:1161-1168, 2004; discussion 1173-1176, 1181-1184
    • (2004) Oncology , vol.18 , pp. 1161-1168
    • Scheithauer, W.1    Blum, J.2
  • 25
    • 77649213517 scopus 로고    scopus 로고
    • Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors
    • Wood L, Lemont H, Jatoi A, et al: Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Community Oncol 7:23-29, 2010
    • (2010) Community Oncol , vol.7 , pp. 23-29
    • Wood, L.1    Lemont, H.2    Jatoi, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.